Mass effect shock trooper2/18/2023 (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced today that it has expanded its partnership with Agios Pharmaceuticals, Inc. 04, 2021 (GLOBE NEWSWIRE) - Centogene N.V. Providing Global Clinical Trial Support for Thalassemia and Sickle Cell Disease Will Deepen Understanding of Disease Characterization in the Search for a TreatmentĬAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, Nov.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |